The @ most commonly recorded adverse events were rash ( @ % ) , fatigue ( @ % ) , and diarrhea ( @ % ) in the erlotinib group and fatigue ( @ % ) , nausea ( @ % ) , and anorexia ( @ % ) in the pemetrexed group .